Fundraising Fox

Aileron Therapeutics

NASDAQ: RNTX

Cambridge, US · Founded 2025 · Delaware corporation · 17 employees on LinkedIn · 2 known investors

Biotech

Founders & leadership

MA
Manuel AivadoExecutive

Board

CW
Caleb WinderinBoard directorManaging Director at Excel Venture Management
SL
Seth L. HarrisonBoard director
RJ
Reinhard J. AmbrosBoard director
JA
Joseph A. Yanchik IIIinCo-Founder, CEO & Director2005–2018Venture Partner at Apple Tree Venture Management Llc
BM
Brian M. Gallagher, Jr.Board director
AS
Armen ShanafeltBoard director
SK
Scott KapnickBoard director
EP
Enrico PetrilloBoard director
JH
John H. McArthurBoard director

Investors · 2

Excel Venture Managementreported · 2 sourcesBoston · $1M – $5Mvia Caleb Winder · board
Novartis Venture FundreportedBasel · $5M – $25M

Reported raises · per SEC filings

Form D private placements

$68.2M disclosed across 3 rounds · 2014–2023

▶$18.3MraisedNov 2023 · 15 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Alan MussoDirector
  • Reinhard J. AmbrosDirector
  • Nolan Sigal, M.D., Ph.D.Director
  • William FaireyDirector
  • Josef H. von RickenbachDirector
  • Manuel Alves-Aivado, M.D., Ph.D.Executive Officer, Director
  • Brian Windsor, Ph.D.Executive Officer
  • Susan L. DrexlerExecutive Officer
Offering amount
$18.3M
Amount sold
$18.3M
Sales commissions
$752.8K
Placement agents
Arcadia Securities, LLC, Clear Street LLC
First sale
Nov 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$30.1MraisedJan 2017 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Manuel AivadoExecutive Officer
  • Caleb WinderDirector
  • Seth L. HarrisonDirector
  • John H. McArthurDirector
  • Reinhard J. AmbrosDirector
  • Joseph A. Yanchik IIIExecutive Officer, Director
  • Brian M. Gallagher, Jr.Director
  • Armen ShanafeltDirector
  • Scott KapnickDirector
Offering amount
$40M
Amount sold
$30.1M
First sale
Dec 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$19.8MraisedOct 2014 · 13 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Joseph A. Yanchik IIIExecutive Officer, Director
  • Seth L. HarrisonDirector
  • Brian M. Gallagher, Jr.Director
  • Armen ShanafeltDirector
  • Reinhard J. AmbrosDirector
  • Scott KapnickDirector
  • John H. McArthurDirector
  • Enrico PetrilloDirector
Offering amount
$33M
Amount sold
$19.8M
First sale
Oct 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

2 people who came through Aileron Therapeutics went on to found or lead other companies.

Jodie MorrisonMember Board Of DirectorsFounded Q32 BioRosana KapellerVice President of ResearchFounded ROME Therapeutics

In the news

Aileron straps in for 2025 with a new name: Rein Therapeuticsfiercepharma.com · Jan 2025Aileron Therapeutics Announces Completion of $35.9 Million Registered Direct Offering with ... | AP Newsapnews.com · Jan 2021Aileron Therapeutics Secures $30 Million in New Financingglobenewswire.com · Nov 2013Aileron Therapeutics raises another $12M – Boston Heraldbostonherald.com · Jan 2013Aileron Therapeutics Closes $40 Million Series D Financing | Fierce Biotechfiercebiotech.com · Jun 2009Aileron Therapeutics Announces $7 Million in Funding - BioSpacebiospace.com · Jun 2007

Frequently asked questions

Who are Aileron Therapeutics's investors?
Aileron Therapeutics's investors include Excel Venture Management, Novartis Venture Fund.
How much funding has Aileron Therapeutics raised?
Aileron Therapeutics has disclosed $68.2M raised across 3 rounds.
Where is Aileron Therapeutics headquartered?
Aileron Therapeutics is headquartered in Cambridge, US.